GRI — GRI Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1824293 ·
Last close
$2.05
Market Cap
$4.48M
52W High
$64.12
52W Low
$1.36
ADV30
417,893
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,648,000 | -1,643,000 | 11,380,000 | 10,947,000 | 1,100,000 |
| Mar 2026 | 0 | — | -2,003,000 | -1,998,000 | 11,339,000 | 11,048,000 | 794,000 |
| Dec 2025 | 0 | — | -2,664,000 | -2,659,000 | 8,666,000 | 8,229,000 | 2,658,000 |
| Sep 2025 | 0 | — | -3,365,000 | -3,359,000 | 4,782,000 | 4,055,000 | 2,789,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,135,000
Investing CF
$0
Financing CF
$19,905,000
CapEx
—
Dividends Paid
—
Buybacks
$-1,000
EPS Diluted TTM
$-236.43
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-53,694,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-10,929,000
Pretax Income TTM
$-10,908,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,977,000 | -11,956,000 | 8,666,000 | 2,658,000 | 6,008,000 | -10,186,000 |
| Dec 2024 | 0 | -8,235,000 | -8,207,000 | 5,739,000 | 1,707,000 | 4,032,000 | -8,611,000 |
| Dec 2023 | 0 | -11,387,000 | -13,037,000 | 2,956,000 | 2,697,000 | 259,000 | -8,990,000 |
| Dec 2022 | 0 | -2,239,000 | -3,217,000 | 383,000 | 2,008,000 | -1,625,000 | -1,085,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-7,657,000
OpCashFlow TTM
$0
Assets (Latest)
$8,666,000
Forward EPS
$-2.00
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ONCO | Onconetix, Inc. | $4.51M | $1.03 | — |
| ADXN | Addex Therapeutics Ltd. | $4.62M | $3.65 | — |
| CANF | Can-Fite BioPharma Ltd. | $4.63M | $2.16 | — |
| EMMA | Emmaus Life Sciences, Inc. | $4.76M | $0.07 | — |
| PMHS | Polomar Health Services, Inc. | $4.82M | $0.17 | — |
News headlines (Yahoo Finance, 1h cache)
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
2026-09-28 12:40 · Yahoo
GRI Bio Featured in "Why Now" On-Demand Video Webcast
2026-08-27 13:01 · Yahoo
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
2026-08-24 13:05 · Yahoo
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
2026-05-18 13:15 · Yahoo
GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?
2026-09-14 16:00 · Yahoo
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
2026-09-08 12:15 · Yahoo
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
2026-06-18 12:31 · Yahoo
Grainger H1 Earnings Call Highlights
2026-05-14 11:05 · Yahoo
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Im
2026-05-14 12:35 · Yahoo
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
2026-04-08 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.